HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Craig M. McDonald, MD, on Safety and Efficacy of DMD Cell Therapy

The principal investigator of the HOPE-2 trial discussed safety and efficacy of Capricor’s CAP-1002.

“We think that the therapy is going to preserve critical arm function that's important to maintain activities of daily living, such as feeding, dressing, scratching the nose, or even hugging a parent... those would be enhanced by this therapeutic.”

Capricor Therapeutics’ CAP-1002, an allogeneic cardiosphere-derived cell therapy, has yielded statistically significant clinical benefits in non-ambulatory patients with Duchenne muscular dystrophy (DMD).1 These newly released data, from the phase 2 HOPE-2 trial open-label extension (OLE; NCT04428476), showed that the trial met its primary endpoint of improvement on Performance of the Upper Limb 2.0 (P = .02) The OLE included 12 patients out of the original 20 from the HOPE-2 trial (NCT05126758). CAP-1002 is also being evaluated in the phase 3 HOPE-3 trial (NCT05126758), in which the first patient with late-stage DMD was recently dosed.2

CGTLive spoke with Craig M. McDonald, MD, chair, Department of Physical Medicine & Rehabilitation and professor, Department of Pediatrics and Physical Medicine & Rehabilitation, UC Davis Health, to learn more about the efficacy and safety data seen in the HOPE-2 trial. He also discussed nest steps for CAP-1002, including the current HOPE-3 trial.

REFERENCES
1. Capricor Therapeutics announces statistically significant clinical benefits in skeletal muscle function in non-ambulant Duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 open label extension study. News release. Capricor Therapeutics. June 27, 2022. Accessed July 20, 2022. https://feeds.issuerdirect.com/news-release.html?newsid=7075005202651835.
2. Capricor Therapeutics announces first patient dosed in pivotal phase 3 study of CAP-1002 for the treatment of Duchenne muscular dystrophy. News release. Capricor Therapeutics. July 19, 2022. Accessed July 20, 2022. https://feeds.issuerdirect.com/news-release.html?newsid=7011515935297837